Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,

Published byShon Harmon Modified over 6 years ago

Similar presentations

Presentation on theme: "A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,"— Presentation transcript:

1 A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Tetsu Shinkai, MD, PhD, Kenji Eguchi, MD, PhD, Yuichiro Ohe, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Masahiro Tsuboi, MD, PhD, Soichiro Yokota, MD, PhD, Takashi Seto, MD, PhD, Haiyi Jiang, MD, Kazuto Nishio, MD, PhD, Nagahiro Saijo, MD, PhD, Masahiro Fukuoka, MD, PhD  Journal of Thoracic Oncology  Volume 3, Issue 4, Pages (April 2008) DOI: /JTO.0b013e318168d228 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Study design. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318168d228) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan–Meier curve for time to progression.
Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318168d228) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Observed maximum vandetanib plasma concentration at day 28. Patients who received dose reduction within the first 28 days were excluded. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318168d228) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Kaplan–Meier curve of low (below median) versus high (above median) baseline plasma VEGF and time to progression. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318168d228) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,"

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304  Martin J. Edelman, MD, Lydia.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB   Martin J. Edelman, MD, Lydia.
Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,
Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR.

Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR.
A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers  Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers  Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer  Peter M.

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer  Peter M.
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.

Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors  Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors  Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Similar presentations

Ads by Google